ribavirin has been researched along with Neutropenia in 73 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.37) | 18.7374 |
| 1990's | 1 (1.37) | 18.2507 |
| 2000's | 37 (50.68) | 29.6817 |
| 2010's | 34 (46.58) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Iqbal, S; Raza, A; Yousaf, MI; Yousuf, MH | 1 |
| Fazylov, VC; Guryanova, SV; Manapova, ER | 1 |
| Hindi, NN; Saleh, MI | 1 |
| Casado, JL; Dronda, F; Hermida, JM; Moreno, A; Moreno, S; Navas, E; Pérez-Elías, MJ; Quereda, C; Royuela, A; Serrano-Villar, S | 1 |
| Abbas, SM; El-Feky, HM; Hegab, MF; Lashin, AH; Metwally, MA; Shaheen, YA | 1 |
| Cao, ZH; Chen, XY; Du, XF; Guo, DD; Liu, YL; Lu, JF; Ma, LN; Zhang, YH | 1 |
| Backus, LI; Belperio, PS; Cheung, R; Mole, LA; Shahoumian, TA | 1 |
| Anagnostou, O; Andreadis, I; Deutsch, M; Kalafateli, M; Ketikoglou, I; Manolakopoulos, S; Mela, M; Papatheodoridis, G; Pectasides, D; Schini, M; Striki, A; Triantos, C | 1 |
| Andriulli, A; Cozzolongo, R; Fontana, R; Iacobellis, A; Ippolito, A; Minerva, N; Niro, GA; Palmieri, O; Valvano, MR | 1 |
| Angeli, E; Caputo, A; Cattelan, AM; Iannacone, C; Maida, I; Nasta, P; Pontali, E; Puoti, M; Verucchi, G | 1 |
| Beumont-Mauviel, M; De La Rosa, G; Forns, X; Fried, MW; Fu, M; Jacobson, IM; Jessner, W; Kalmeijer, R; Lenz, O; Manns, MP; Ouwerkerk-Mahadevan, S; Peeters, M; Poordad, F; Scott, JA; Sinha, R; Zeuzem, S | 1 |
| Gattei, V; Mauro, E; Mazzaro, C | 1 |
| Ahn, SB; Choe, WH; Chung, JI; Jun, DW; Jung, KS; Kim, DY; Kim, JK; Kim, SG; Kim, W; Lee, SH; Park, SY; Seo, YS; Shim, JJ; Shin, HP | 1 |
| Kim, HJ; Lee, HW; Lee, YJ; Park, SJ; Yang, SY; Yoo, KY | 1 |
| Besheer, M; El-Karaksy, HM; El-Raziky, MS; Mogahed, EA; Mubarak, S; Saleh, D | 1 |
| Banhegyi, D; Bergin, C; Chernova, O; DeMasi, R; Doroana, M; Gori, A; Hadacek, B; Liu, C; Nelson, M; Rockstroh, JK; Verucchi, G | 1 |
| Ahlers, S; Bakalos, G; Coppola, C; Derbala, M; Ferenci, P; Foster, GR; Hassanein, T; Orlandini, A; Reddy, KR; Shiffman, ML; Tallarico, L | 1 |
| Berden, FA; Blokzijl, H; de Knegt, RJ; den Hollander, J; Drenth, JP; Friederich, P; Kievit, W; Kuiken, SD; van Erpecum, KJ; van Hoek, B; van Nieuwkerk, CM; van Vonderen, MG; Willemse, SB | 1 |
| Chan, A; Everson, GT; Fried, MW; Ghalib, R; Godofsky, E; Harrison, S; Hill, G; Najera, I; Nelson, D; Nyberg, L; Pockros, PJ; Rodriguez-Torres, M; Shiffman, ML | 1 |
| Kristian, P; Pellová, A; Porubcin, S; Schréter, I | 1 |
| Ferenci, P | 1 |
| Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Huang, JF; Lin, ZY; Wang, LY; Yang, JF; Yu, ML | 1 |
| Ben-Ari, Z; Braun, M; Cohen, M; Cohen-Ezra, O; Katz, L; Manhaim, V; Rotman, Y; Tur-Kaspa, R | 1 |
| Higaki, K; Ide, T; Karashima, T; Maeyama, Y; Narita, K; Okamura, S; Sakai, T; Sata, M; Sumie, H; Yoshikai, H | 1 |
| Archimandritis, A; Elefsiniotis, J; Koskinas, J; Kostopoulos, P; Kotsiou, S; Kountouras, D; Savvas, S; Schina, M; Sidiropoulos, J; Zacharakis, G | 1 |
| Celiento, M; De Rosa, A; Ripa, C; Schiano, A; Tambaro, O; Tarantino, L | 1 |
| Alba, LM; Bulchandani, D; Nachnani, JS; Pandya, PK; Rao, GA | 1 |
| Poll, R | 1 |
| Alvarez-Uria, G; Day, JN; Nasir, AJ; Russell, SK; Vilar, FJ | 1 |
| Mac Nicholas, R; Norris, S | 1 |
| Cheong, HR; Cho, M; Heo, J; Kang, DH; Kim, DU; Kim, GH; Song, GA; Woo, HY; Yoon, KT | 1 |
| Bakulin, IG; Sharabanov, AS | 1 |
| de Knegt, RJ; Hansen, BE; Janssen, HL; Roomer, R | 1 |
| Balistreri, WF; Barton, BA; Gonzalez-Peralta, RP; Goodman, Z; Haber, BA; Jonas, MM; Lobritto, SJ; Mohan, P; Molleston, JP; Murray, KF; Narkewicz, MR; Robuck, PR; Rosenthal, P; Rossi, S; Schwarz, KB; Smith, L; Valsamakis, A | 1 |
| Hegarty, JE; Norris, S; O'Farrelly, C; Ryan, EJ; Tajuddin, T | 1 |
| Doucette, K; Dryden, DM; Durec, T; Fassbender, K; Tandon, P; Vandermeer, B | 1 |
| Afdhal, NH; Albrecht, JK; Brass, CA; Clark, PJ; Esteban, R; Fellay, J; Galler, GW; Ge, D; Goldstein, DB; Jacobson, IM; King, JW; Kwo, PY; Lawitz, EJ; McCone, J; McHutchison, JG; Muir, AJ; Naggie, S; Noviello, S; Patel, K; Pedicone, LD; Poordad, F; Shianna, KV; Shiffman, ML; Singh, A; Sulkowski, MS; Thompson, AJ; Tillmann, HL; Urban, TJ; Zhu, M; Zhu, Q | 1 |
| Kang, P; Sun, LJ; Yan, BZ; Yu, JW; Zhao, YH | 2 |
| Battyáni, Z; Hunyady, B; Kovács, B | 1 |
| Beem, LW; Morse, ML | 1 |
| Fazio, V; Giannini, EG; Marenco, S; Picciotto, A; Pieri, G; Savarino, V | 1 |
| Berak, H; Dusheiko, GM; Ferenci, P; Gane, EJ; Hadziyannis, SJ; Han, KH; Harley, HA; Horsmans, YJ; Husa, P; Jenny Heathcote, E; Lee, SS; Messinger, D; Roberts, SK; Tatsch, F | 1 |
| Gournay, J; Richou, C | 1 |
| Doo, E; Everhart, JE; Ghany, MG; Heller, T; Hoofnagle, JH; Liang, TJ; Park, Y; Promrat, K; Soza, A | 1 |
| Afdhal, NH | 1 |
| Antonini, MG; Babudieri, S; Baiguera, C; Carosi, G; Fenu, L; Maida, I; Mura, MS; Puoti, M; Putzolu, V; Rezza, G; Rossi, S; Sassu, S; Viale, P; Zanini, B | 1 |
| Ong, JP; Younossi, ZM | 1 |
| Gonzalez, SA; Jacobson, IM | 1 |
| Collantes, R; Gujral, H; Viscomi, C | 1 |
| Kowdley, KV | 1 |
| Collantes, RS; Younossi, ZM | 1 |
| Assor, P; Bacq, Y; d'Alteroche, L; Gaudy, C; Lefrou, L; Senecal, D | 1 |
| Afdhal, NH; Curry, MP | 1 |
| Casillas-Davila, L; Chirino-Sprung, R; Dehesa-Violante, M; Díaz-Hernandez, M; Juarez-Navarro, A; Navarro, JM; Vera-de-León, L | 1 |
| Sulkowski, MS | 1 |
| Broissand, C; Fontaine, H; Lebray, P; Nalpas, B; Pol, S; Serpaggi, J; Sobesky, R; Vallet-Pichard, A | 1 |
| Becker, MC; Bresson-Hadni, S; Bronowicki, JP; Di Martino, V; Lunel-Fabiani, F; Miguet, JP; Thevenot, T; Vanlemmens, C | 1 |
| Franke, G; Lange, T; Niederwieser, D | 1 |
| Deschênes, M; Hilzenrat, N; Nudo, CG; Wong, P | 1 |
| Dar Santos, AE; Ford, JA; Partovi, N; Yoshida, EM | 1 |
| Arora, S; Gish, RG; Murphy, B; Nelson, DR; O'Brien, C; Rajender Reddy, K; Xu, Y | 1 |
| Bacon, BR; Barange, K; Harley, H; Lin, A; Nelson, D; Shafran, SD; Shiffman, ML; Solá, R; Soman, A; Suter, F; Zeuzem, S | 1 |
| Bolokadze, N; Gochitashvili, N; Sharvadze, L; Tophuria, A; Tsertsvadze, T | 1 |
| Adamski, A; Blessman, D; Gandotra, SD; Htwe, TH; Khardori, NM; Koirala, J; Mushtaq, A; Rao, S; Sangwan, G | 1 |
| Llopis González, A; Márquez Peiró, JF; Morales Suárez-Varela, M; Pérez Peiró, C; Valero Alcocer, VE | 1 |
| Manfredi, R; Sabbatani, S | 1 |
| Esposito, S; Hamzeh, FM; Rustgi, VK; Shiffman, ML | 1 |
| Bai, C; Collantes, R; Fang, Y; Farmer, D; Gujral, H; Gurung, C; Nader, FH; Ong, JP; Ramsey, L; Sjogren, M; Sjogren, R; Srishord, M; Terra, K; Younossi, ZM | 1 |
| Arizcorreta-Yarza, A; Collado, A; Fernández-Fuertes, E; Girón-González, JA; González-Serrano, M; López-Cortés, LF; Lozano, F; Macías, J; Merino, D; Mira, JA; Pineda, JA; Ríos-Villegas, MJ; Rivero, A; Torres-Tortoso, M; Valera-Bestard, B | 1 |
| Antonini, MG; Babudieri, S; Baiguera, C; Carosi, G; Dettori, G; Fenu, L; Maida, I; Manno, D; Mura, MS; Puoti, M; Zanini, B | 1 |
| Anaissie, E; Aslan, T; Barlogie, B; Desikan, R; Fassas, AB; Mehta, J; Munshi, N; Siegel, D; Singhal, S | 1 |
| Bishop, J; Coates, A; Fox, R; Grygiel, J; Raghavan, D; Sampson, D; Woods, R | 1 |
16 review(s) available for ribavirin and Neutropenia
| Article | Year |
|---|---|
Peginterferon and ribavirin in HCV: improvement of sustained viral response.
Topics: Anemia; Antiviral Agents; Clinical Trials as Topic; Depression; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Medication Adherence; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Thrombocytopenia; Treatment Outcome | 2008 |
The role of the community nurse in hepatitis C diagnosis and treatment.
Topics: Antiviral Agents; Community Health Nursing; Depression; Drug Monitoring; Fatigue; Hepatitis C; Humans; Infection Control; Interferon alpha-2; Interferon-alpha; Neutropenia; Nurse's Role; Nursing Assessment; Patient Education as Topic; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; Social Support; United Kingdom | 2009 |
Review article: optimizing SVR and management of the haematological side effects of peginterferon/ribavirin antiviral therapy for HCV - the role of epoetin, G-CSF and novel agents.
Topics: Anemia; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erythropoietin; Granulocyte Colony-Stimulating Factor; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thrombocytopenia; Viral Load | 2010 |
Granulocyte colony-stimulating factor for hepatitis C therapy-associated neutropenia: systematic review and economic evaluation.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Granulocyte Colony-Stimulating Factor; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2011 |
[Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
Topics: Affect; Anemia, Hypochromic; Antiviral Agents; Autoimmune Diseases; Autoimmunity; Cardiovascular System; Clinical Trials as Topic; Drug Eruptions; Drug Synergism; Drug Therapy, Combination; Endocrine System Diseases; Eye; Hepatitis C, Chronic; Humans; Infections; Interferon alpha-2; Interferon-alpha; Neutropenia; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Respiratory System; Ribavirin; Risk Factors; Thrombocytopenia | 2011 |
[Treatment of chronic hepatitis C: side effects, tolerability and quality of life].
Topics: Anemia, Hemolytic; Antiviral Agents; Blood Cell Count; Clinical Trials as Topic; Controlled Clinical Trials as Topic; Depressive Disorder; Drug Therapy, Combination; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Kidney Transplantation; Liver Transplantation; Mental Disorders; Neutropenia; Prospective Studies; Quality of Life; Retrospective Studies; Ribavirin; Risk Factors; Thrombocytopenia; Time Factors | 2002 |
Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia.
Topics: Anemia; Antiviral Agents; Clinical Trials as Topic; Darbepoetin alfa; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Filgrastim; Granulocyte Colony-Stimulating Factor; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukin-11; Neutropenia; Patient Compliance; Polyethylene Glycols; Quality of Life; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Thrombocytopenia | 2004 |
The role of hematopoietic growth factors in special populations with chronic hepatitis C: patients with HIV coinfection, end-stage renal disease, or liver transplantation.
Topics: Anemia; Antiviral Agents; Clinical Trials as Topic; Comorbidity; Drug Therapy, Combination; Erythropoietin; Forecasting; Granulocyte Colony-Stimulating Factor; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Kidney Failure, Chronic; Liver Transplantation; Neutropenia; Patient Compliance; Recombinant Proteins; Recurrence; Renal Dialysis; Ribavirin | 2004 |
The role of physician extenders in managing patients with chronic hepatitis C.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Neutropenia; Nurse Practitioners; Patient Compliance; Patient Education as Topic; Physician Assistants; Quality of Health Care; Ribavirin; Risk Factors; Social Support; Thrombocytopenia | 2004 |
Hematologic side effects of interferon and ribavirin therapy.
Topics: Anemia, Hypochromic; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Erythropoietin; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thrombocytopenia | 2005 |
The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin.
Topics: Anemia, Hypochromic; Antiviral Agents; Darbepoetin alfa; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Granulocyte Colony-Stimulating Factor; Growth Substances; Hematinics; Hematologic Diseases; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thrombocytopenia | 2005 |
Use of growth factors with antiviral therapy for chronic hepatitis C.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon Type I; Neutropenia; Patient Compliance; Quality of Life; Recombinant Proteins; Ribavirin; Thrombocytopenia | 2005 |
Management of the hematologic complications of hepatitis C therapy.
Topics: Anemia; Antiviral Agents; Bone Marrow; Epoetin Alfa; Erythropoietin; Hematologic Diseases; Hepatitis C, Chronic; Humans; Interferon Type I; Neutropenia; Recombinant Proteins; Ribavirin; Thrombocytopenia | 2005 |
[Complementary treatments of chronic viral hepatitis C].
Topics: Anemia; Antidepressive Agents; Antioxidants; Antiviral Agents; Erythropoietin; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thrombocytopenia | 2006 |
Use of hematopoietic growth factors as adjuvant therapy for anemia and neutropenia in the treatment of hepatitis C.
Topics: Anemia; Chemotherapy, Adjuvant; Epoetin Alfa; Erythropoietin; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematinics; Hepatitis C; Humans; Interferons; MEDLINE; Neutropenia; Recombinant Proteins; Ribavirin | 2007 |
Patients with multiple myeloma may safely undergo autologous transplantation despite ongoing RSV infection and no ribavirin therapy.
Topics: Aged; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Immunoglobulins, Intravenous; Incidence; Male; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Pilot Projects; Respiratory Syncytial Virus Infections; Ribavirin; Transplantation Conditioning | 1999 |
20 trial(s) available for ribavirin and Neutropenia
| Article | Year |
|---|---|
Sofosbuvir Adverse Events Profile in a Subset of Pakistani Population.
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Neutropenia; Pancytopenia; Ribavirin; Sofosbuvir; Thrombocytopenia; Treatment Outcome | 2018 |
A population pharmacodynamic model characterizing neutropenia associated with pegylated interferon alpha 2-a therapy in patients with chronic hepatitis C viral infection.
Topics: Adult; Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Leukocyte Count; Male; Middle Aged; Models, Biological; Neutropenia; Neutrophils; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2018 |
Cytopenias during treatment of HIV-HCV-coinfection with pegylated interferon and ribavirin: safety analysis of the OPERA study.
Topics: Adult; Anemia; Antiviral Agents; Cell Count; Coinfection; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thrombocytopenia; Viral Load | 2015 |
Highly effective peginterferon α-2a plus ribavirin combination therapy for chronic hepatitis C in hemophilia in Korea.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Fatigue; Female; Genotype; Headache; Hemophilia A; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Recurrence; Republic of Korea; Ribavirin; RNA, Viral; Treatment Outcome | 2015 |
Telaprevir-based therapy for treatment of HIV-1 and hepatitis C virus co-infected patients: An early access programme.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Bilirubin; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Neutropenia; Oligopeptides; Ribavirin; RNA, Viral; Young Adult | 2015 |
Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort.
Topics: Adult; Aged; Anemia; Antiviral Agents; Asthenia; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Interferon-alpha; Male; Middle Aged; Neutropenia; Outcome Assessment, Health Care; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Ribavirin; RNA, Viral; Withholding Treatment | 2016 |
R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antiviral Agents; Cytidine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance, Viral; Drug Synergism; Drug Therapy, Combination; Female; Hepacivirus; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neutropenia; Nucleosides; Polyethylene Glycols; Prodrugs; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2008 |
Low weight predicts neutropenia and peginterferon alfa-2a dose reductions during treatment for chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Body Mass Index; Body Surface Area; Body Weight; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Young Adult | 2009 |
Granulocyte colony stimulating factor in HCV genotype-1 patients who develop Peg-IFN-alpha2b related severe neutropenia: a preliminary report on treatment, safety and efficacy.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Granulocyte Colony-Stimulating Factor; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocyte Count; Male; Middle Aged; Neutropenia; Neutrophils; Patient Compliance; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Severity of Illness Index; Treatment Outcome | 2009 |
Lenograstim in the treatment of severe neutropenia in patients treated with Peg-IFN and ribavirin: the experience of a single hepatology unit.
Topics: Antiviral Agents; Biopsy; Drug Administration Schedule; Drug Therapy, Combination; Granulocyte Colony-Stimulating Factor; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lenograstim; Liver; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
[Clinical significance of leukopenia and neutropenia patients with chronic hepatitis "C" in the various regimes antiretroviral therapy].
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukopenia; Liver Cirrhosis; Male; Middle Aged; Moscow; Neutropenia; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome | 2010 |
The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2011 |
Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients.
Topics: Adult; Anemia; Antiviral Agents; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Internationality; Liver Cirrhosis; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Thrombocytopenia; Treatment Outcome | 2012 |
Virological response and safety outcomes in therapy-nai ve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study.
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Thrombocytopenia; Treatment Outcome | 2007 |
Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.
Topics: Adult; Anemia; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2007 |
IFN/RBV treatment induced neutropenia and its correction with neupogen in patients with hepatitis C.
Topics: Adult; Antiviral Agents; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Neutropenia; Recombinant Proteins; Ribavirin | 2007 |
[Toxicity of the treatment of chronic hepatitis C with peginterferon alpha (2a or 2b) plus ribavirin in patients not previously treated].
Topics: Alanine Transaminase; Antiviral Agents; Bilirubin; Cohort Studies; Drug Therapy, Combination; Fatigue; Fever; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Neutropenia; Patient Dropouts; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Viral Load | 2007 |
Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin.
Topics: Adult; Anemia; Antiviral Agents; Depression; Drug Administration Schedule; Drug Therapy, Combination; Drug Tolerance; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multicenter Studies as Topic; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Surveys and Questionnaires; Thrombocytopenia; Time Factors; Viral Load | 2008 |
A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment.
Topics: Adult; Anemia; Antiviral Agents; Darbepoetin alfa; Erythropoietin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematinics; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2008 |
Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.
Topics: Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Infections; Interferon alpha-2; Interferon-alpha; Leukocyte Count; Male; Middle Aged; Neutropenia; Neutrophils; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2008 |
37 other study(ies) available for ribavirin and Neutropenia
| Article | Year |
|---|---|
[Cytopenias and their correction during antiviral therapy of chronic hepatitis C in patients with genotype 1].
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thrombocytopenia; Treatment Outcome | 2017 |
Neutropenia during therapy with peginterferon and ribavirin in HIV-infected subjects with chronic hepatitis C and the risk of infections.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Middle Aged; Neutropenia; Opportunistic Infections; Prospective Studies; Ribavirin; Risk Assessment | 2013 |
Incidence and predictors of hematological side effects in chronic HCV Egyptian patients treated with PEGylated interferon and ribavirin.
Topics: Adolescent; Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Egypt; Female; Hematologic Diseases; Hepatitis C, Chronic; Humans; Interferon-alpha; Leukocyte Count; Liver Cirrhosis; Male; Middle Aged; Neutropenia; Neutrophils; Platelet Count; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Thrombocytopenia; Young Adult | 2013 |
Bone marrow suppression or active proliferation? An analysis of neutropenia after pegylated interferon treatment of patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Bone Marrow Cells; Cytokines; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Statistics, Nonparametric; Young Adult | 2013 |
Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort.
Topics: Antiviral Agents; Cohort Studies; Comparative Effectiveness Research; Female; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Neutropenia; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin; Thrombocytopenia; United States; Veterans | 2014 |
Cirrhosis but not neutropenia is associated with the development of infection in patients with chronic hepatitis C undergoing treatment with pegylated interferon-alpha and ribavirin.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Bacterial Infections; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Neutropenia; Retrospective Studies; Ribavirin; Young Adult | 2014 |
Feasibility of pegylated interferon and ribavirin in hepatitis C-related cirrhosis with neutropenia or thrombocytopenia.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Epistaxis; Esophageal and Gastric Varices; Feasibility Studies; Female; Gastrointestinal Hemorrhage; Gingival Hemorrhage; Hepatitis C, Chronic; Humans; Infections; Interferon-alpha; Leukocyte Count; Liver Cirrhosis; Male; Middle Aged; Neutropenia; Neutrophils; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Thrombocytopenia | 2014 |
Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies.
Topics: Anemia; Antiviral Agents; Bilirubin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Controlled Clinical Trials as Topic; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Exanthema; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Neutropenia; Prevalence; Pruritus; Ribavirin; Simeprevir | 2015 |
Recombinant Human Erythropoietin (RHuEpo) and Granular Colony Stimulating Factor (G-CSF) in hepatitis C virus (HCV) related to mixed cryoglobulinaemia associated to membranoproliferative glomerulonephritis type I: a case report description.
Topics: Anemia; Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Erythropoietin; Glomerulonephritis, Membranoproliferative; Granulocyte Colony-Stimulating Factor; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Neutropenia; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome | 2014 |
Efficacy and safety of pegylated interferon base treatment in patients with chronic hepatitis C on dialysis.
Topics: Adult; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Male; Middle Aged; Neutropenia; Patient Dropouts; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Republic of Korea; Retrospective Studies; Ribavirin; Treatment Outcome | 2015 |
Safety and Efficacy of Combined Treatment with Pegylated Interferon Alpha-2b and Ribavirin for HCV Genotype 4 in Children.
Topics: Adolescent; Antiviral Agents; Body Height; Body Weight; Child; Child, Preschool; Drug Administration Schedule; Drug Therapy, Combination; Female; Fever; gamma-Glutamyltransferase; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Leukocyte Count; Male; Neutropenia; Neutrophils; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Surveys and Questionnaires; Treatment Outcome; Viral Load | 2016 |
Limited Generalizability of Registration Trials in Hepatitis C: A Nationwide Cohort Study.
Topics: Adult; Aged; Anemia; Antiviral Agents; Cardiovascular Diseases; Eligibility Determination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Neoplasms; Netherlands; Neutropenia; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Regression Analysis; Retrospective Studies; Ribavirin; Risk Factors | 2016 |
[Haematologic adverse effects of treatment of chronic viral hepatitis B and C].
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thrombocytopenia | 2008 |
Bacterial infection and neutropenia during peginterferon plus ribavirin combination therapy in patients with chronic hepatitis C with and without baseline neutropenia in clinical practice.
Topics: Adult; Aged; Antiviral Agents; Bacterial Infections; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome; Young Adult | 2009 |
[Case of overwhelming postsplenectomy infection (OPSI) with chronic hepatitis type C during peginterferon/ribavirin combination therapy].
Topics: Antiviral Agents; Fatal Outcome; Female; Hepatitis C, Chronic; Humans; Immunocompromised Host; Interferon alpha-2; Interferon-alpha; Middle Aged; Neutropenia; Pneumococcal Infections; Pneumococcal Vaccines; Polyethylene Glycols; Postoperative Complications; Recombinant Proteins; Ribavirin; Sepsis; Splenectomy | 2009 |
Predictors of hematological abnormalities in patients with chronic hepatitis C treated with interferon and ribavirin.
Topics: Adult; Anemia; Antiviral Agents; Female; Genotype; Hematologic Diseases; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Multivariate Analysis; Neutropenia; Ribavirin; Risk Factors; Thrombocytopenia | 2010 |
Reduction in neutrophil count during hepatitis C treatment: drug toxicity or predictor of good response?
Topics: Adult; Antiviral Agents; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neutropenia; Neutrophils; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Risk Assessment; RNA, Viral; Statistics, Nonparametric; Treatment Outcome; Viral Load | 2010 |
[Clinical efficacy and safety of the combination therapy of peginterferon alpha and ribavirin in cirrhotic patients with HCV infection].
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Neutropenia; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Severity of Illness Index; Treatment Outcome | 2010 |
Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Bacterial Infections; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Infections; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors | 2010 |
Interferon-α suppressed granulocyte colony stimulating factor production is reversed by CL097, a TLR7/8 agonist.
Topics: Adult; Aged; Antiviral Agents; Case-Control Studies; Cells, Cultured; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Granulocyte Colony-Stimulating Factor; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Ireland; Leukocyte Count; Male; Middle Aged; Neutropenia; Neutrophils; Polyethylene Glycols; Prospective Studies; Quinolines; Recombinant Proteins; Ribavirin; Time Factors; Toll-Like Receptor 7; Toll-Like Receptor 8; Treatment Outcome | 2010 |
Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients.
Topics: Adult; Antiviral Agents; Female; Genome-Wide Association Study; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukopenia; Linkage Disequilibrium; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Ribavirin; Thrombocytopenia | 2012 |
The study of relationship between neutropenia and infection during treatment with peginterferon α and ribavirin for chronic hepatitis C.
Topics: Adult; Age Factors; Antiviral Agents; Diabetes Complications; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Immunocompromised Host; Interferon-alpha; Leukocyte Count; Liver Cirrhosis; Male; Middle Aged; Neutropenia; Opportunistic Infections; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors | 2011 |
Benefits of Reiki therapy for a severely neutropenic patient with associated influences on a true random number generator.
Topics: Anxiety; Consciousness; Hematocrit; Hepacivirus; Hepatitis C; Humans; Interferons; Leukocyte Count; Male; Middle Aged; Mind-Body Relations, Metaphysical; Neutropenia; Neutrophils; Ribavirin; Severity of Illness Index; Spirituality; Therapeutic Touch | 2011 |
Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy.
Topics: Adolescent; Adult; Age Factors; Aged; Anemia; Antiviral Agents; Contraindications; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Practice Guidelines as Topic; Prevalence; Retrospective Studies; Ribavirin; Thrombocytopenia; Young Adult | 2012 |
[A study of the relationship between neutropenia and clinical infection risk during treatment with peginterferon alfa-2a and ribavirin for chronic hepatitis C].
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Infections; Interferon-alpha; Leukocyte Count; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors | 2012 |
Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C.
Topics: Adult; Antiviral Agents; Black People; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Infections; Interferon-alpha; Leukocyte Count; Male; Middle Aged; Neutropenia; Neutrophils; Prevalence; Retrospective Studies; Ribavirin; United States; White People | 2002 |
Role of epoetin alfa in maintaining ribavirin dose.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Hematinics; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thrombocytopenia | 2004 |
Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation?
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Infections; Interferon alpha-2; Interferon Type I; Interferon-alpha; Italy; Longitudinal Studies; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Respiratory Tract Infections; Retrospective Studies; Ribavirin | 2004 |
[Severe autoimmune neutropenia and thrombopenia associated with chronic C hepatitis: effect of antiviral therapy].
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neutropenia; Purpura, Thrombocytopenic, Idiopathic; Recombinant Proteins; Ribavirin; RNA, Viral | 2005 |
Incidence and severity of infections according to the development of neutropenia during combined therapy with pegylated interferon-alpha2a plus ribavirin in chronic hepatitis C infection.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocyte Count; Logistic Models; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
The impact of haematopoietic growth factors on the management and efficacy of antiviral treatment in patients with hepatitis C virus.
Topics: Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2005 |
Parotitis associated with a parainfluenza virus type 3 infection during aplasia after unrelated allogeneic stem cell transplantation.
Topics: Adult; Hematopoietic Stem Cell Transplantation; Humans; Leukemia-Lymphoma, Adult T-Cell; Male; Neutropenia; Parainfluenza Virus 3, Human; Parotitis; Respirovirus Infections; Ribavirin; Transplantation, Homologous | 2006 |
Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C.
Topics: Adult; Age Factors; Aged; Anemia; Antiviral Agents; Biomarkers; Blood Cell Count; Blood Platelets; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Male; Middle Aged; Neutropenia; Neutrophils; Polyethylene Glycols; Quebec; Recombinant Proteins; Ribavirin; Risk Factors; Severity of Illness Index; Thrombocytopenia; Treatment Outcome | 2006 |
Granulocyte colony-stimulating factor dosing in pegylated interferon alpha-induced neutropenia and its impact on outcome of anti-HCV therapy.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocyte Count; Logistic Models; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome | 2007 |
Multiple, repeated filgrastim treatment cycles to recover severe, recurring pegylated interferon-related neutropenia.
Topics: Adult; Antiviral Agents; Filgrastim; Genotype; Granulocyte Colony-Stimulating Factor; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome | 2007 |
Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients.
Topics: Adult; Anemia; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Fibrosis; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Leukocyte Count; Male; Neutropenia; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Spain; Thrombocytopenia; Zidovudine | 2007 |
Phase I and pharmacokinetic study of tiazofurin (NSC 286193) administered by 5-day continuous infusion.
Topics: Adult; Chromatography, High Pressure Liquid; Conjunctivitis; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Female; Humans; Kinetics; Male; Middle Aged; Neoplasms; Neutropenia; Ribavirin; Ribonucleosides | 1986 |